Michigan-based Esperion Therapeutics, Inc. (ESPR) plans to align its expense and operational structure to boost the growth of NEXLIZET and NEXLETOL oral medicines.
Esperion Therapeutics Inc (NASDAQ:ESPR) and Nektar Therapeutics (NASDAQ:NKTR) are skyrocketing with a fury today on back of major clinical strides forward that have investors …
Esperion Therapeutics Inc (NASDAQ:ESPR) announced the initiation of the global cardiovascular outcomes trial (CVOT) to assess the effects of bempedoic acid on the …
In a research report released Thursday, Chardan Capital analyst Gbola Amusa reiterated a Neutral rating on shares of Esperion Therapeutics Inc (NASDAQ:ESPR), with a …
Esperion Therapeutics, Inc. (NASDAQ:ESPR) announced the bempedoic acid global pivotal Phase 3 LDL-C lowering clinical development program will include patients with hypercholesterolemia on any …
Galena Biopharma Inc (NASDAQ:GALE) is plummeting 80% in early morning trading after the company discontinued its phase 3 interim analysis on Neuvax, its …
Esperion Therapeutics Inc (NASDAQ:ESPR), a late-stage pharmaceutical company focused on developing and commercializing first-in-class oral therapies for the treatment of patients with elevated low …
Esperion Therapeutics Inc (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of …
Esperion Therapeutics Inc (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment …